atenolol 50 mg daily and nifedipine 40 mg daily. Detailed enquiry revealed that he had had several episodes of palpitations, anxiety and headaches while taking this treatment. On examination the blood pressure was 180/80 mmHg. During the second day of admission an episode of chest pain occurred with T-wave inversion on the ECG. The blood pressure was 220/120 mmHg and a labetalol infusion was started. Five minutes after the start of the infusion the blood pressure rose to 230/130 mmHg and the patient had a grand mal fit. A phaeochromocytoma was suspected, the labetalol was stopped and a phenoxybenzamine infusion started. The blood pressure became well controlled and no further fits occurred. The 24-hour urinary free noradrenaline level was 36 300 nmol/l (normal <880 nmol/l) and a CT scan revealed a 6-cm left adrenal mass which later showed uptake with radiolabelled meta-iodobenzyl-guanidine. After further treatment with phenoxybenzamine and propranolol, the mass was resected and confirmed histologically to be a phaeochromocytoma. Two years after surgery he remains normotensive and requires no medication.

Catecholamines act at α - and β -adrenergic receptors. Activation of α -adrenoreceptors mediates vasoconstriction, while activity at β_1 -adrenoreceptors may cause cardiac palpitations and arrhythmias, but β_2 -receptors also vasodilate arterioles, especially in skeletal muscle. This vasodilatation may protect the patient. If this 'protective' β_2 -action is blocked, unopposed activity at α -adrenoreceptors (including vasoconstriction) may lead to a phaeochromocytoma crisis. Case 1 illustrates the catastrophic effects of prolonged unopposed α -adrenergic activity after propranolol. The drug was continued for four days before correct treatment was started, and the intense vasoconstriction appeared to lead to severe end-organ damage and eventually death. In case 2, intravenous labetalol, which has only weak α -blocking activity, exacerbated the hypertension and this probably induced the fit. There have been several reports of worsening of hypertension in phaeochromocytoma patients treated with labetalol,³⁻⁵ and alternative drugs are available.⁶ Furthermore, labetalol may interfere with the measurement of urinary catecholamines.⁷

Several cases of hypertensive crisis or pulmonary oedema have been reported in phaeochromocytoma patients treated with propranolol prior to α -blockade,⁸⁻¹⁰ sometimes with a fatal outcome if the correct diagnosis is not made quickly.¹¹

While β -blockers do play a role in the management of phaeochromocytomas, they should only be used after full α -adrenoceptor blockade. Phaeochromocytomas are rare, and propranolol is a widely used, cheap and effective drug for treating essential hypertension.¹² Nevertheless, if any patient deteriorates after starting a β -adrenergic blocker, the drug should be stopped and the patient investigated as a matter of urgency. Finally, if a phaeochromocytoma is diagnosed, a β -blocking drug should only be given after full α -adrenoreceptor blockade.

R SHEAVES
SL CHEW

AB GROSSMAN

Department of Endocrinology,
St Bartholomew's Hospital,
London EC1A 7BE, UK

- 1 Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. *Mayo Clin Proc* 1983; **58**: 802-4.
- 2 Prichard BNC. Combined alpha- and beta-inhibition in the treatment of hypertension. *Drugs* 1984; **28** (suppl 2): 51-68.
- 3 Briggs RSJ, Birtwell AJ, Pohl JEF. Hypertensive response to labetalol in phaeochromocytoma. *Lancet* 1978; **1**: 1045-6.
- 4 Feek CM, Earnshaw PM. Hypertensive response to labetalol in phaeochromocytoma. *BMJ* 1980; **281**: 387.
- 5 Navaratnarajah M, White DC. Labetalol and phaeochromocytoma. *Br J Anaesthesiol* 1984; **56**: 1179.
- 6 Calhoun DA, Oparil S. Treatment of hypertensive crisis. *N Engl J Med* 1990; **323**: 1177-83.
- 7 Bouloux P, Perrett D. Interference of labetalol metabolites in the determination of plasma catecholamines by HPLC with electrochemical detection. *Clin Chim Acta* 1985; **150**: 111-7.
- 8 Wark JD, Larkins RG. Pulmonary oedema after propranolol therapy in two cases of phaeochromocytoma. *BMJ* 1978; **1**: 1395-6.
- 9 Blodgett J, Reasner CA. Transient thyrotoxicosis associated with a pheochromocytoma in a patient with multiple endocrine neoplasia type 2a. *Am J Med* 1990; **88**: 302-3.
- 10 Ober KP. Pheochromocytoma in a patient with hyperthyroxinemia. *Am J Med* 1991; **90**: 137-8.
- 11 Sloan EM, Thompson BT. Propranolol-induced pulmonary edema and shock in a patient with pheochromocytoma. *Arch Intern Med* 1984; **144**: 173-4.
- 12 Sever P, Beevers G, Bulpitt C *et al.* Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. *BMJ* 1993; **306**: 983-7.

AIDS and dilated cardiomyopathy

Sir,

Acquired immunodeficiency syndrome (AIDS) is increasingly recognised as an important aetiological factor in dilated cardiomyopathy.¹ Echocardiographic features consistent with dilated cardiomyopathy have been reported in 30 to 40% of patients with AIDS. Moreover, with the increasing success in treating opportunistic infections many patients will now survive to develop human immune-deficiency virus (HIV) cardiomyopathy and succumb to congestive heart failure. The pathogenesis of HIV cardiomyopathy, and particularly its relation to myocarditis, has not been established, and there is only a loose correlation between myocarditis and the development of HIV-dilated cardiomyopathy. I suggest an important mechanism which may be, at least in part, responsible.

Several studies have shown increased serum levels of tumour necrosis factor- α (TNF) in AIDS patients, and that this increase is positively correlated with the severity of the disease. This cytokine has recently been shown to play an important role in the pathogenesis of AIDS and of many disorders associated with the latter.² Elevated levels of serum TNF may induce significant myocardial depression, directly by depressing myocyte shortening, and indirectly by the release of secondary mediators, such as nitric oxide (NO) and oxygen-free radicals.³

NO is released in response to TNF which induces the expression and synthesis of NO synthase in endothelial cells and other cells including macrophages and smooth muscle cells. It has recently been demonstrated that NO is also produced within the myocytes themselves. Two forms of NO synthase have been identified. The first is the constitutive calcium-dependent NO synthase (CNOS), which synthesizes the major component of endothelium-derived relaxing factor. The

second is the inducible, calcium-independent enzyme (INOS), which is induced by endotoxin or cytokines, particularly TNF, and predominates in vascular smooth muscle. Synthesis of NO by this pathway in the vessel wall is involved in the vasodilatation and probably, the tissue damage of endotoxic shock.^{3,4} It has been demonstrated that normal rat myocardium contains CNOS and expresses INOS during endotoxaemia, and that isolated rat myocytes express INOS only after stimulation with cytokines.⁴ Furthermore, it has been shown recently that heart tissue from patients with dilated cardiomyopathy showed significant INOS activity, while CNOS activity was 10-11-fold lower or not detectable.⁴ Several recent studies have shown that NO may induce myocardial depression, and that the negative inotropic effects of TNF on the heart may partly be mediated by NO.³ Furthermore, it has also been demonstrated that inhibitors of NO and NO synthase can decrease significantly the depressed myocardial contractility induced both by NO itself and by TNF.³

TNF promotes local and systemic release of oxygen-free radicals, particularly from activated neutrophils. Several studies have demonstrated that oxygen-free radicals depress cardiac function and myocardial contractility, and that scavengers of oxygen-free radicals may protect the heart from their deleterious effects.³

The above data strongly suggest an important role for TNF in the development of myocardial dysfunction and dilated cardiomyopathy in AIDS patients. Indeed, it has been shown that chronic treatment with TNF may cause a permanent decrease in myocardial contractility and ultimately dilated cardiomyopathy.⁵ Antagonists of TNF and of NO, and scavengers of oxygen-free radicals may therefore have important therapeutic benefits in preventing the development of HIV cardiomyopathy.

MAJED ODEH

Department of Internal Medicine B,
Bnai Zion Medical Center, and
Technion Faculty of Medicine,
Israel Institute of Technology,
Haifa, Israel

- 1 Kaul S, Fishbein MC, Siegel RJ. Cardiac manifestations of acquired immunodeficiency syndrome: a 1991 update. *Am Heart J* 1991; **122**: 535-44.
- 2 Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? *AIDS* 1991; **5**: 1405-17.
- 3 Odeh M. Tumor necrosis factor- α as a myocardial depressant substance. *Int J Cardiol* 1993; **42**: 231-8.
- 4 De Belder AJ, Radomski MW, Why HJF, *et al.* Nitric oxide synthase activities in human myocardium. *Lancet* 1993; **341**: 84-5.
- 5 Hegewisch S, Weh H-J, Hossfeld DK. TNF-induced cardiomyopathy. *Lancet* 1990; **335**: 294-5.

Gross cholestatic dysfunction in giant cell arteritis

Sir,

Mild to moderate hepatic dysfunction is a common observation during the acute phase of temporal arteritis and polymyalgia rheumatica but gross cholestatic dysfunction is unusual.

A 75-year-old woman was admitted with sudden bilateral blindness over a period of five days. Over the previous few weeks she

had suffered from headaches, and generalised aches and pains. On examination both temporal arteries were thickened, nonpulsatile and tender. She was completely blind in the left eye with vision in the right eye diminished to hand movements. The right fundus showed a pale swollen disc and a few retinal haemorrhages, and the left optic disc looked atrophic. Investigations revealed Hb of 10 g/dl, erythrocyte sedimentation rate (ESR) 115 mm/h; liver function tests were markedly deranged with elevation in alkaline phosphatase to 3750 IU/l ($n = 80-350$), γ -glutamyl transferase (γ -GT) to 769 IU/l ($n < 55$) and aspartate aminotransferase (AST) to 129 IU/l ($n = 7-35$), normal bilirubin, low albumin of 29 g/l ($n = 35-52$) and total protein of 56 g/l ($n = 63-80$). HBsAg and anti-HBs (anti-HCV not available at the time) were negative and an autoimmune profile was normal. Ultrasound examination of the abdomen showed normal liver and biliary system. Occipital artery biopsy showed the classical features of giant cell arteritis.

She was initially treated with high-dose dexamethasone with improvement in the right eye vision from hand movements to 6/9 36 h later but she remained blind in the left eye. She was started on prednisolone 60 mg daily and remained on a maintenance dose of 10-15 mg daily. Three months later there was improvement in the liver function tests. Liver biopsy performed at this stage showed nonspecific fatty changes and portal tract and intralobular infiltration with inflammatory cells and mild bile stasis in the biliary canaliculi.

There are several reports of mild to moderate hepatic dysfunction in association with polymyalgia rheumatica/temporal arteritis.¹ The commonest abnormality is mild to moderate elevation of alkaline phosphatase with or without changes in the liver enzymes. Retention of bromsulphalein has been observed to be the common abnormality in some series and a striking correlation between the magnitude of the increase in alkaline phosphatase with ESR and bromsulphalein retention has been noted.²

Hypoalbuminaemia and increase in alpha-1 and alpha-2 globulins are frequently noted during the acute phase of this illness. Mild to moderate disturbance of liver enzymes and prolonged prothrombin time have also been described.^{1,3} All these abnormalities have been shown to return promptly to normal following steroid therapy.

Histopathological studies of the liver biopsies from patients with polymyalgia rheumatica/temporal arteritis are limited. They are predominantly reported to be normal or to show nonspecific changes and occasionally presence of granulomas.^{1,2} Von Knorring and Wasastjerna² have demonstrated structural changes in the biliary canaliculi in the form of widening and irregularity of the canalicular wall. Recently, one of the present authors (KNA) has reported changes of ultrastructural injury to biliary canaliculi in a case of biopsy proven temporal arteritis.⁴ The pathogenesis and significance of these hepatic changes remains uncertain.

Clinically, our patient had a widespread arteritic process. It is likely that the hepatic arteries were involved in the generalised

vasculitic process, producing marked hepatic enzyme abnormalities which returned to normal over a period of six months on steroid therapy.

KESARAKODI N ACHAR

RICHARD P ASHFIELD

West Dorset General Hospitals NHS Trust,
Dorset County Hospital,
Dorchester, Dorset DT1 1TS, UK

- 1 Holdstock G, Milward-Sadler GH, Wright R. Hepatic changes in systemic disease. In: Wright R, Milward-Sadler GH, Alberti KGMM, Karan S, eds. *Liver and biliary disease*, 2nd edn. Bailliere Tindall-WB Saunders Company, 1985; pp 1033-76.
- 2 Von Knorring J, Wasastjerna C. Liver involvement in polymyalgia rheumatica. *Scand J Rheumatol* 1976; 5: 197-204.
- 3 Dickson ER, Maladonado E, Sheps SG, Cain JA. Systemic giant cell-arteritis with polymyalgia rheumatica. *JAMA* 1973; 224: 1496-8.
- 4 Achar KN, Al-Alousi SS, Patrick JP. Biliary ultrastructural changes in the liver in a case of giant cell arteritis. *Br J Rheumatol* 1994; 33: 161-4.

Attitudes of junior medical staff to requesting permission for autopsy

Sir,

Hinchcliffe *et al* make some interesting observations in relation to the attitudes of junior medical staff towards autopsy requests and we believe that these issues merit further discussion.¹ The recommendations of the joint working party of the Royal Colleges, which included the Royal College of Physicians of London, clearly state that the responsibility for obtaining consent for autopsies lies with the consultant in charge of the case.² Whilst this responsibility may be delegated, this should be a positive act and appropriate training in how to request permission for autopsies is the proper duty of senior clinicians. Those individuals responsible for approaching the relatives should be formally trained to ensure a sympathetic and informative approach.

The provision of undergraduate communication skills training in relation to bereavement does not appear to incorporate situation-specific applications such as obtaining consent for autopsies and the process does not continue into postgraduate medical education.³ The process of requesting an autopsy from recently bereaved relatives is stressful and any sense of personal discomfort will decrease the motivation of clinicians to request autopsies.⁴ This indifference may be reinforced by unpleasant demonstration facilities, a lack of interest amongst clinical colleagues and hostile relatives who themselves have been influenced by the medical community's failure to appreciate the role of the modern autopsy.

The latter point is supported by the present study in which many of the respondents were found to be unaware of the potential benefits of autopsies. Those clinicians who receive appropriate training may have more confidence and consequently may be more willing to take the time to educate relatives in the nature and the importance of the autopsy.

The manner in which permission for autopsy is sought is important and can influence the decision of the family in approximately one third of cases.⁵ Any significant improvement in autopsy request techniques should stimulate more autopsy requests of a higher standard. Increasing the number and quality of autopsy requests is probably the only basis upon which autopsy rates will ever be improved.

RD START

SJ SHERWOOD

University of Sheffield Medical School
Beach Hill Road,
Sheffield S10 2UL, UK

- 1 Hinchcliffe SA, Godfrey HW, Hind CRK. Attitudes of junior medical staff to requesting permission for autopsy. *Postgrad Med J* 1994; 70: 292-4.
- 2 Royal College of Pathologists, Royal College of Physicians and the Royal College of Surgeons. Autopsy and audit. *A Report of a Joint Working Party*. London, 1991.
- 3 Frederikson L, Bull P. An appraisal of the current status of communication skills training in British Medical schools. *Soc Sci Med* 1992; 34: 515-22.
- 4 Sherwood SJ. *Motivation to request permission for hospital autopsies: the predictive utility of clinicians' strength of self-efficacy, outcome expectations and outcome values*. Thesis (MSc). University of Sheffield.
- 5 Gardner R, Peskin L, Katz JL. The physician, the autopsy request and the consent rate. *J Med Educ* 1973; 48: 636-44.

Clinical presentation of orthostatic hypotension in the elderly

Sir,

Dr Craig's excellent account of the neurological complications of postural hypotension covered most manifestations of this syndrome.¹ An additional feature worth mentioning is the presentation with transient focal neurological signs due to co-existing critical stenosis of the carotid or vertebral arteries.² In some of these patients the postural fall in systolic blood pressure may be as little as 10 mmHg (Case 2 in the report by Stark *et al*).² This may be sufficient to compromise blood flow through a stenotic internal carotid artery, thereby giving rise to focal weakness on assuming the erect posture. Sometimes transient hemiparesis may be the result of aggravation of postural hypotension by postprandial hypotension,³ and this serves as a reminder that clinicians should always ascertain the relationship of focal neurological signs not only to posture but also to meals.

OMP JOLOBE

Department of Medicine for the Elderly,
Tameside General Hospital,
Ashton under Lyne,
Lancashire OL6 9RW, UK

- 1 Craig GM. Clinical presentation of orthostatic hypotension in the elderly. *Postgrad Med J* 1994; 70: 638-42.
- 2 Stark RJ, Wodak J. Primary orthostatic cerebral ischemia. *J Neurol Neurosurg Psychiatry* 1983; 46: 883-91.
- 3 Kamata T, Yokota T, Furukawa T, *et al*. Cerebral ischemic attack caused by postprandial hypotension. *Stroke* 1994; 25: 511-3.